Hints and tips:
Related Special Reports
...Ogilvy, which has previously worked with a host of pharma groups including Pfizer and Johnson & Johnson, is launching a business that offers vetted influencers to talk about illnesses and possible solutions...
...Johnson & Johnson has struck a deal to buy medical device maker Shockwave Medical for $13.1bn, as the healthcare giant puts cash to work from the spin-off of its consumer health arm to pursue acquisitions...
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Ginger Graham, a board member since 2010 and former chief of Amylin Pharmaceuticals, will fill the chief executive role while it searches for “a successor with deep healthcare experience”....
...Johnson & Johnson, one of the world’s largest healthcare companies, is facing thousands of lawsuits from people alleging they got cancer from using one of their oldest products: talc-based baby powder....
...Johnson & Johnson reported a first-quarter loss as it booked a $6.9bn charge linked to its proposal to settle tens of thousands of legal claims related to allegations its talcum powder caused cancer....
...Shares of Kenvue, the consumer arm of healthcare giant Johnson & Johnson, jumped on their first day of trading after an upsized initial public offering that marked the biggest US listing in almost 18 months...
...In a recent high-profile case, the tactic was used by Johnson & Johnson, the US pharmaceuticals group. “The Texas two-step, which is what J&J did, well OK, let’s look at that. Does it make sense?...
...But mild over-the-counter remedies have lost their power to make shareholders in Johnson & Johnson feel good....
...Janssen is the pharmaceutical division of J&J....
...US healthcare company Johnson & Johnson’s global legal team developed a risk management tool in Asia-Pacific first, in part because it felt those lawyers would be more receptive to innovation than others...
...It costs the US $219bn a year in healthcare services and lost productivity. Johnson & Johnson thinks there is money to be made in the cardiovascular field....
...Risk management Winner: Johnson & JohnsonOriginality: 8; Leadership: 9; Impact: 9; Total: 26The litigation team in Asia-Pacific designed a digital system for the pharmaceutical business to improve its management...
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
...A coalition of ethical investors have asked Johnson & Johnson, Merck, Pfizer, Eli Lilly, Gilead, Amgen, Regeneron, Bristol Myers Squibb and AbbVie to publish a report on the process they follow when applying...
...Johnson & Johnson announced in November it had struck a deal to acquire cardiovascular technology group Abiomed for $16.6bn, while Pfizer said in May it had agreed to buy US biotech Biohaven Pharmaceuticals...
...However, large pharmaceutical and healthcare companies — including those such as J&J that have benefited from the cash generated by Covid-19 vaccine sales — have been in a better position to strike deals...
...Some healthcare experts believe the vaccine could win over vaccine sceptics who have so far resisted getting jabs....
...Johnson & Johnson said it was negotiating partnership deals with two Chinese companies as it taps into a biotech boom in the country driven by a surge in private investment and government support, according...
...Johnson & Johnson is to spin off its consumer products division, best known for Band-Aids and baby shampoo, as the world’s largest healthcare company seeks to focus on pharmaceuticals and medical devices...
...Two doses of the Johnson & Johnson Covid-19 vaccine cut the risk of hospitalisation by up to 85 per cent, according to a South African study conducted when the Omicron coronavirus variant was dominant....
...Johnson & Johnson must seize its “golden moment” and break up, outgoing chief executive Alex Gorsky has told investors at the world’s biggest healthcare company....
...Johnson & Johnson has finally decided to let shareholders do their own portfolio diversification. The world’s largest healthcare company plans to split itself in two....
...“Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in pharmaceuticals, ongoing recovery in medical devices, and strong growth in Consumer...
International Edition